Hydroxymethylnitrofurazone (NFOH) decreases parasitaemia, parasitism and tissue lesion caused by infection with the Bolivia Trypanosoma cruzi type I strain in Swiss and C57BL/6 mice

Caue Benito Scarim; Cleverton Roberto  de Andrade; Rossana Falcone; Leticia Moreno; Vitor  Senhorelli; João A Da Rosa; Chung  Man Chin

doi:10.1590/s2175-97902022e20277

Authors

Caue Benito Scarim Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of Pharmaceuticals and Medicines, Araraquara, SP, Brazil https://orcid.org/0000-0002-2540-6395
Cleverton Roberto de Andrade Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Dentistry, Department of Physiology and Pathology, Araraquara, SP, Brazil
Rossana Falcone Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of biosciences and biotechnology, Araraquara, SP, Brazil
Leticia Moreno Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of biosciences and biotechnology, Araraquara, SP, Brazil
Vitor Senhorelli Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of Pharmaceuticals and Medicines, Araraquara, SP, Brazil
João A Da Rosa Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of biosciences and biotechnology, Araraquara, SP, Brazil
Chung Man Chin Sao Paulo State University “Júlio de Mesquita Filho”, UNESP, Faculty of Pharmaceutical Sciences, Department of Pharmaceuticals and Medicines, Araraquara, SP, Brazil

DOI:

https://doi.org/10.1590/s2175-97902022e20277

Keywords:

Chagas disease, Trypanosoma cruzi, Bolivia strain, Acute stage, Hydroxymethylnitrofurazone (NFOH), Benznidazole (BZN)

Abstract

The chemical hydroxymethylation of the antimicrobial nitrofurazone leads to the prodrug NFOH, also increases the anti-T. cruzi activities (in vitro and in vivo), as well as showed non-genotoxic (Ames and micronucleus assays). In the present study, we assessed the anti-T. cruzi effect of the NFOH In vivo - in acute Swiss and C57Bl/6 experimental Chagas models. The treatment started at 5 days post-infection during 20 consecutive days (orally, once day, 150mg/kg), and the parasitaemia as well as histopathology analysis were performed. In both experimental murine models, NFOH was able to reduce parasitemia blood avoiding parasitic reactivation, during immunosuppression period (dexamethasone 5mg/kg, 14 days), in 100% of the mice, and decrease tissue parasite nests, demonstrating absence of amastigote forms in all organs (100%) analyzed, data similar to benznidazole (BZN). Therefore, the results shown here pointing to the NFOH as promising compound for further preclinical studies, being a high potential drug to effective and safe chemotherapy to Chagas disease.

Downloads

Download data is not yet available.

References

Andrade AL de, Zicker F, Oliveira RM de, Almeida Silva S, Luquetti A, Travassos LR, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 1996;348(9039):1407-13. doi:10.1016/ S0140-6736(96)04128-1.

» https://doi.org/10.1016/ S0140-6736(96)04128-1

Andrade MC, Oliveira MDF, Nagao-Dias AT, Coêlho IC, Cândido D da S, Freitas EC, et al. Clinical and serological evolution in chronic Chagas disease patients in a 4-year pharmacotherapy follow-up: a preliminary study. Rev Soc Bras Med Trop. 2013;46(6):776-778. doi:https://doi. org/10.1590/0037-8682-1646-2013.

» https://doi.org/https://doi. org/10.1590/0037-8682-1646-2013

Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas ’ disease (American trypanosomiasis). Hum Exp Toxicol. 2006;25:471-79.

Cortez-Maya S, Moreno-Herrera A, Palos I, Rivera G. Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Diseases or New Options for Other Diseases?. Curr Med Chem. 2020;27(32):5403-5428.

Chagas C. Nova tripanozomiase humana. Estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen. n. sp., agente etiolójico de uma nova entidade mórbida do homem. Mem Inst Oswaldo Cruz. 1909;1(2):159-218.

Chung MC, Güido RVC, Martinelli TF, Gonçalves MF, Polli MC, Botelho KCA, et al. Synthesis and in vitro evaluation of potential antichagasic hydroxymethylnitrofurazone (NFOH-121): A new nitrofurazone prodrug. Bioorg Med Chem. 2003;11(22):4779-83.

Davies C, Cardozo RM, Negrette OS, Mora MC, Chung MC, Basombrío MA. Hydroxymethylnitrofurazone is active in a murine model of Chagas’ disease. Antimicrob Agents Chemother. 2010;54(9):3584-9.

Davies C, Dey N, Negrette OS, Parada LA, Basombrio MA, Garg NJ. Hepatotoxicity in Mice of a Novel Anti-parasite Drug Candidate Hydroxymethylnitrofurazone: A Comparison with Benznidazole. PLoS Negl Trop Dis. 2014;8(10):e3231.

DNDi. Drugs for Neglected Diseases initiative (DNDi), Neglected Tropical Diseases. https://www.dndi.org/diseases-projects/chagas/ (Accessed 25 February 2021). 2018.

» https://www.dndi.org/diseases-projects/chagas/

Ekins S, de Siqueira-Neto JL, McCall LI, Sarker M, Yadav M, Ponder EL, et al. Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery. PLoS Negl Trop Dis . 2015;9(6):e0003878

Fernandes CD, Tiecher FM, Balbinot MM, Liarte DB, Scholl D, Steindel M, et al. Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Mem Inst Oswaldo Cruz . 2009;104(1):27-32. doi:https://doi. org/10.1590/S0074-02762009000100004.

» https://doi.org/https://doi. org/10.1590/S0074-02762009000100004

Fernandez ML, Marson ME, Ramirez JC, Mastrantonio G, Schijman AG, Altcheh J, et al. Pharmacokinetic and pharmacodynamics responses in adult patients with Chagas disease treated with a new formulation of benznidazole. Mem Inst Oswaldo Cruz . 2016;111(3):218-21. doi:https://doi. org/10.1590/0074-02760150401.

» https://doi.org/https://doi. org/10.1590/0074-02760150401

Guido RVC, Ferreira EI, Nassute JC, Varanda EA, Chung MC. Diminuição da atividade mutagênica do pró-fármaco NFOH-121 em relação ao nitrofural (nitrofurazona). Rev Ciênc Farm. 2001;22(2):319-33.

Hasslocher-Moreno AM, do Brasil PEAA, de Sousa AS, Xavie SS, Chambela MC, Sperandio da Silva GM. Safety of benznidazole use in the treatment of chronic Chagas’ disease. J Antimicrob Chemother. 2012;67(5):1261-66. DOI:https:// doi.org/10.1093/jac/dks027

» https://doi.org/https:// doi.org/10.1093/jac/dks027

Lidani KCF, Andrade FA, Bavia L, Damasceno FS, Beltrame MH, Messias-Reason IJ, et al. Chagas Disease: From Discovery to a Worldwide Health Problem. Front Public Health. 2019;7:1-13. DOI:10.3389/fpubh.2019.00166

» https://doi.org/10.3389/fpubh.2019.00166

Maya JD, Orellana M, Ferreira J, Kemmerling U, López-Muñoz R, Morello A. Chagas disease: present status of pathogenic mechanisms and chemotherapy. Biol Res. 2010;43(3):323-31.doi:https://doi.org/10.4067/S0716-97602010000300009.

» https://doi.org/https://doi.org/10.4067/S0716-97602010000300009

Nogueira-Filho MAF, Carvalho EC, De Campos ML, Machado DVP, Davanço MG, Pestana KC, et al. Pharmacokinetics of Hydroxymethylnitrofurazone and Its Parent Drug Nitrofurazone in Rabbits. Drug Metab Lett. 2013;7(1):58-64.

Ribeiro V, Dias N, Paiva T, Hagström-Bex L, Nitz N, Pratesi R, et al. Current trends in the pharmacological management of Chagas disease. Int J Parasitol Drugs Drug Resist. 2020;10(12):7-17.

Scarim CB, Chung CM. Nitroheterocyclic derivatives: privileged scaffold for drug development against Chagas disease. Med Chem Res. 2019;28(12):2099-108.

Scarim CB, de Andrade CR, da Rosa JA, dos Santos JL, Chung MC. Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study. Int J Exp Pathol. 2018a;99(5):236-48.

Scarim CB, Jornada DH, Chelucci RC, De Almeida L, Dos Santos JL, Chung CM. Current advances in drug discovery for Chagas disease. Eur J Med Chem. 2018b;155:824-838.

Serafim EOP, Silva ATA, Moreno AH, Vizioli EO, Ferreira EI, Peccinini RG, et al. Pharmacokinetics of hydroxymethylnitrofurazone, a promising new prodrug for chagas’ disease treatment. Antimicrob Agents Chemother . 2013;57(12):6106-9.

Silva GMS Da, Mediano MF, Alvarenga Americano do Brasil PE, da Costa Chambela M, da Silva JA, de Sousa AS, et al. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazolE. Antimicrob Agents Chemother . 2014;58(1):6371-77. doi:10.1128/AAC.02842-14.

» https://doi.org/10.1128/AAC.02842-14

Sosa-Estani S, Segura E, Ruiz A, Velazquez E, Porcel B, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas’ disease. Am J Trop Med Hyg. 1998;59(4):526-9.

Soy D, Aldasoro E, Guerrero L, et al. Population pharmacokinetics of benznidazole in adult patients with Chagas disease. Antimicrob Agents Chemother . 2015;59(6):3342-49. doi:https://doi.org/10.1128/AAC.05018-14.

» https://doi.org/https://doi.org/10.1128/AAC.05018-14